

Pediatric Pancreas Transplant Recipient Follow-Up Worksheet

FORM APPROVED: O.M.B. NO. 0915-0157 Expiration Date: 10/31/2010

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI[®] application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI[®] application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information	
Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
Previous Follow-Up:	Previous Px Stat Date:
Transplant Discharge Date:	
State of Permanent Residence:*	
Zip Code:*	-
Provider Information	
Recipient Center:	
Followup Center:	
Physician Name: *	
NPI#:*	
Follow-up Care Provided By:*	 Transplant Center Non Transplant Center Specialty Physician Primary Care Physician Other Specify
Specify:	
Donor Information	
UNOS Donor ID #:	
Donor Type:	
Болог туре.	
Patient Status	
Date: Last Seen, Retransplanted or Death*	
Patient Status: ≭	C LIVING C DEAD

© RETRANSPLANTED		
Primary Cause of Death: Specify:		
Contributory Cause of Death: Specify:		
Contributory Cause of Death: Specify:		
Hospitalizations: Has the patient been hospitalized since the last patient status date: * Number of Hospitalizations:	C YES C NO C UNK ST=	
Noncompliance: Was there evidence of noncompliance with immunosuppression medication during this follow-up period that compromised the patient's recovery:	C YES O NO UNK	
Functional Status: *		
Cognitive Development:*	 Definite Cognitive delay/impairment Probable Cognitive delay/impairment Questionable Cognitive delay/impairment No Cognitive delay/impairment Not Assessed 	
Motor Development:*	C Definite Motor delay/impairment C Probable Motor delay/impairment C Questionable Motor delay/impairment C No Motor delay/impairment C Not Assessed	

	Within One Grade Level of Peers
	C Delayed Grade Level
Academic Progress: *	Special Education
	Not Applicable < 5 years old/ High School graduate or GED
	Status Unknown
	Full academic load
	Reduced academic load
Academic Activity Level:*	Unable to participate in academics due to disease or condition
	Not Applicable < 5 years old/ High School graduate or GED
	C Status Unknown
Primary Insurance at Follow-up:★	
Specify:	
Clinical Information	
Date of Measurement:	ft. in. cm ST=
Height: * Weight: *	ft. in. cm ST=
	/m ²
9	····
Graft Status: *	Functioning Partial Function Failed
If death is indicated for the recipient, and the dea	ath was a result of some other factor unrelated to graft failure, select Functioning.
	☐ Insulin
	Oral medication
Method of blood sugar control:	Diet
	No Treatment
Date insulin/medication resumed:	
Date of Failure:	
Pancreas Graft Removed:	C YES ONO UNK
Date Pancreas Removed:	
Primary Cause of Graft Failure:	

Other, Specify:	
Contributory causes of graft failure:	
Graft/Vascular Thrombosis:	C YES O NO C UNK
Infection:	C YES NO UNK
Bleeding:	C YES NO UNK
Anastomotic Leak:	C YES NO UNK
Acute Rejection:	YES NO UNK
Chronic Rejection:	YES NO UNK
Biopsy Proven Isletitis:	C YES O NO O UNK
Pancreatitis:	C YES O NO O UNK
Patient Noncompliance	YES NO UNK
Other, Specify:	
Conv. From Bladder to Enteric Drain Performed: ★	C YES O NO C UNK
If Yes, Enteric Drainage Date:	
Serum Amylase:	u/L ST=
Most Recent Serum Creatinine: ★	mg/dl ST=
Pancreas Transplant Complications (Not leading	to graft failure):
Pancreatitis:*	YES NO UNK
Anastomotic Leak: *	YES NO UNK
Abcess or Local Infection:★	C YES NO UNK
Other Complications:	
	Yes, at least one episode treated with anti-rejection agent
Did patient have any acute rejection episodes	Yes, none treated with additional anti-rejection agent

	○ No ○ Unknown
Was biopsy done to confirm acute rejection:	 Biopsy not done Yes, rejection confirmed Yes, rejection not confirmed Unknown
Post Transplant Malignancy:*	C YES C NO C UNK
Donor Related:	C YES C NO C UNK
Recurrence of Pre-Tx Tumor:	C YES ONO UNK
De Novo Solid Tumor:	C YES C NO C UNK
De Novo Lymphoproliferative disease and Lymphoma:	C YES C NO C UNK

Treatment	
Biological or Anti-viral therapy:	C YES NO Unknown/Cannot disclose
	Acyclovir (Zovirax)
	Cytogam (CMV)
	Gamimune
If Yes, check all that apply:	☐ Gammagard
	Ganciclovir (Cytovene)
	☐ Valgancyclovir (Valcyte)
	HBIG (Hepatitis B Immune Globulin)

	Flu Vaccine (Influenza Virus)		
	Lamivudine (Epivir) (for treatment of Hepatitis B)		
	☐ Valacyclovir (Valtrex)		
	Other, Specify		
	Ctner, Specify		
Specify: *			
Specify:			
Other therapies:	C YES C NO		
	Photopheresis		
If Yes, check all that apply:	Plasmapheresis		
	Total Lymphoid Irradiation (TLI)		
Immunosuppressive Information			
Previous Validated Maintenance Follow-Up Medications:			
Previous Validated Maintenance Follow-Up Medications:			
	Yes, same as validated TRR form		
Management distributions also designed to follow	Yes, same as previous validated report		
Were any medications given during the follow- up period for maintenance:	Yes, but different than previous validated report		
	None given		
Did the physician discontinue all maintenance immunosuppressive medications:	C YES C NO		
Did the patient participate in any clinical research protocol for immunosuppressive medications:	C YES C NO		
Specify: *			
Immunosuppressive Medications			
View Immunosuppressive Medications			

what reason. If a medication was not given, leave the associated box(es) blank.

Previous Maintenance (Prev Maint) includes all immunosuppressive medications given during the report period, which covers the period from the last clinic visit to the current clinic visit, for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Current Maintenance (Curr Maint) includes all immunosuppressive medications given at the current clinic visit to begin in the next report for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode since the last clinic visit (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

Note: The Anti-rejection field refers to any anti-rejection medications since the last clinic visit, not just at the time of the current clinic visit.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Previous Maint, or Current Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.**

	Prev Maint	Curr Ma	int AR
Steroids (Prednisone,Methylprednisolone,Solumedrol,Medrol,Decadron)			
Atgam (ATG)			
OKT3 (Orthoclone, Muromonab)			
Thymoglobulin			
Simulect - Basiliximab			
Zenapax - Daclizumab			
Azathioprine (AZA, Imuran)			
EON (Generic Cyclosporine)			
Gengraf (Abbott Cyclosporine)			
Other generic Cyclosporine, specify brand:			
Neoral (CyA-NOF)			
Sandimmune (Cyclosporine A)			
CellCept (Mycophenolate Mofetil; MMF)			
Generic MMF (Generic CellCept)			
Prograf (Tacrolimus, FK506)			
Generic Tacrolimus (Generic Prograf)			
Modified Release Tacrolimus FK506E (MR4)			
Sirolimus (RAPA, Rapamycin, Rapamune)			
Myfortic (Mycophenolate Sodium)			

Other Immunosuppressive Medications		
	Prev Maint	Curr Maint AR
Campath - Alemtuzumab (anti-CD52)		
Cyclophosphamide (Cytoxan)		
Leflunomide (LFL, Arava)		
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)	П	
Other Immunosuppressive Medication, Specify		
Rituximab		
Investigational Immunosuppressive Medications		
invocagational immunocappiccone incurcations	Prev Maint	Curr Maint AR
Everolimus (RAD, Certican)		
Other Immunosuppressive Medication, Specify		
UNOS View Only		
Comments:		